Guardian Wealth Management Inc. raised its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 11,848 shares of the company’s stock after buying an additional 438 shares during the quarter. Johnson & Johnson comprises 2.1% of Guardian Wealth Management Inc.’s investment portfolio, making the stock its 15th largest position. Guardian Wealth Management Inc.’s holdings in Johnson & Johnson were worth $2,093,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Glassy Mountain Advisors Inc. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $35,000. Retirement Financial Solutions LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $40,000. TD Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the third quarter worth approximately $48,000. VitalStone Financial LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $52,000. Finally, Iron Horse Wealth Management LLC increased its position in shares of Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after acquiring an additional 159 shares during the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Price Performance
Johnson & Johnson stock opened at $154.41 on Friday. Johnson & Johnson has a one year low of $150.11 and a one year high of $183.35. The business has a fifty day moving average price of $159.89 and a 200-day moving average price of $165.86. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. The firm has a market capitalization of $401.27 billion, a P/E ratio of 32.30, a PEG ratio of 2.67 and a beta of 0.53.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 3.08%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s payout ratio is presently 99.58%.
Insider Buying and Selling
In related news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.20% of the stock is owned by company insiders.
Analysts Set New Price Targets
A number of analysts recently commented on the company. Raymond James decreased their price target on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. Guggenheim assumed coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target for the company. Morgan Stanley increased their price target on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Finally, StockNews.com began coverage on Johnson & Johnson in a report on Thursday, May 18th. They set a “strong-buy” rating for the company. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.